End of Phase 2 Meeting for INV102 (nadolol)
Filed with ASX · · 2 pages · English
Earlier from Invion
- Invion announces no secondary capital raise
- Smoking cessation patent allowance and Operational update
- Appendix 4D and Half Year Accounts
- Invion completes SPP and Placement
- Smoking cessation trial results of ongoing data analysis
Later from Invion
- Phase 2 data presented to American Thoracic Society
- Response to ASX Appendix 4C query
- App 4E, Annual and Financial Report FY2016
- Receipt of R&T tax rebate
- Appendix 4C for the September quarter
Follow Invion into a list and get an email when it puts out news.
Follow Invion